“…Unnecessary recalls increase the cost of screening, may cause psychosocial harm due to false-positive alarms, and can deter women from rescreening [ 11 , 12 ]. Digital breast tomosynthesis (DBT) and ultrasound can mitigate the limitations associated with DM, allowing for a more detailed evaluation of breast tissue and suspicious lesions by minimising superimposition of parenchymal densities [ 13 , 14 , 15 ]. In the United Kingdom National Health Service Breast Screening Programme, DBT assessment of women recalled at DM screening led to a 33% reduction in the benign biopsy rate [ 16 ], with lower false positives across mammographic features such as mass lesions and asymmetric densities.…”